Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$25.20M$25.20M+7,226.2% vs Q3 2022 Net Income-$65.73M-$65.73MN/M vs Q3 2022 EPS Diluted-$0.54-$0.54N/M vs Q3 2022 Operating Income-$73,577,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$75,987,000N/M Margins · derivedOperating margin-291.9%+24676.7 pt vs Q3 2022
Net margin-260.8%+24207.8 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end